Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:05:26.460Z.
Calculation as of: 2026-10-06T12:05:26.460Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$867.60M
EV/EBIT Ratio
N/A
TTM Avg
76.83x
3Y Avg
76.83x
5Y Avg
76.83x
Market Cap
$786.48M
EV/EBIT Ratio
N/A
TTM Avg
501.20x
3Y Avg
422.57x
5Y Avg
422.57x
Market Cap
$903.13M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$776.24M
EV/EBIT Ratio
N/A
TTM Avg
957.13x
3Y Avg
957.13x
5Y Avg
957.13x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | N/A | 9.35x | 9.35x | 9.35x |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 76.83x | 76.83x | 76.83x |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 501.20x | 422.57x | 422.57x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | N/A | 13.71x | 14.97x | 19.98x |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 957.13x | 957.13x | 957.13x |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
